IARC disputes report that attributes most types of cancer to "bad luck"
the ONA take:
Widespread media coverage has been given to a scientific study that compares the number of lifetime stem cell divisions across a wide range of tissues with lifetime cancer risk.
The study suggests that random mutations—or bad luck—are “the major contributors to cancer overall, often more important than either hereditary or external environmental factors.” The study authors argue that focusing on early detection of the disease is more significant than preventive measures.
The World Health Organization’s specialized cancer agency, the International Agency for Research on Cancer (IARC), however, disputes these findings, pointing to a serious contradiction with an extensive body of evidence as well as limitations and biases within the analysis.
Five decades of international epidemiological research demonstrates how most cancers may be prevalent in one population but not in another and that these patterns change over time. For example, colorectal cancer was once rare in Japan, but incidence has increased 4-fold in the past 20 years, an observation consistent with changes in environment and lifestyle exposures. Furthermore, IARC points out that the study emphasizes rare cancers, which make up only a small percentage of cancer cases.
The association between cell divisions and the risk of mutation and, therefore, of developing cancer, is clear; however, most cancers are strongly related to environment and lifestyle. The IARC argues that most common cancers can be prevented as evidenced by the impact of reductions in smoking leading to fewer lung cancer cases or lower rates of hepatocellular carcinoma among people vaccinated against hepatitis B virus.
Although investing in prevention measures for those cancers whose risk factors are known should continue, the IARC stresses that cancer risk should not be ascribed to bad luck.
Continuing the search for the causes of cancer is particularly important, especially in areas of the world with limited resources for facing the growing burden of cancer.
A scientific study compares the number of lifetime stem cell divisions across a wide range of tissues with lifetime cancer risk.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- VBPWPs Can Compliment Patient Management in Clinical Trials
- Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|